Albireo Pharma, Inc. ALBO
At closeMar 2, 2023, 4:00 PM EST
52-week range unavailable
- Market cap
- 915.89M
- Revenue (ttm)
- 57.39M
- Profit margin
- -228.51%
- Shares out
- 20.74M
- Forward P/E
- -6.81
- Volume
- 1.24M
- Open
- 44.90
- Previous close
- 44.15
- Day's range
- 44.00 – 44.90
- Beta
- 1.04
- Analysts
- Hold
- Price target
- 42.00 (-4.9%)
- Earnings date
- Mar 7, 2023
Key statistics
- Enterprise value
- 701.12M
- PEG ratio
- 0.00
- Price / sales
- 15.96
- Price / book
- 9.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 168.30%
- Free cash flow
- -73.51M
- Total cash
- 222.48M
- Total debt
- 9.63M
- Return on equity
- -93.08%
- Short % of float
- 3.49%
- 50-day average
- 38.96
- 200-day average
- 25.30
Analyst view
Consensus: hold
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 7, 2023
Expected Mar 7, 2023. Consensus EPS estimate -1.97.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 7, 2023 | Dec 1, 2022 | -1.80 | — | — | — |
| Nov 8, 2022 | Sep 1, 2022 | -1.86 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -1.58 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -2.02 | — | — | — |
| Mar 1, 2022 | Dec 1, 2021 | -1.27 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | 0.54 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 15, 2023 | HC Wainwright & Co. | reit | — | Neutral |
| Jan 11, 2023 | Guggenheim | down | Buy | Neutral |
| Jan 11, 2023 | Cowen & Co. | down | Outperform | Market Perform |
| Jan 11, 2023 | Jefferies | down | Buy | Hold |
| Jan 10, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jan 9, 2023 | Wedbush | down | Outperform | Neutral |
About Albireo Pharma, Inc.
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- albireopharma.com
News
Albireo Energy Announces CEO Succession as Company Enters Next Stage of Accelerated Expansion 
Albireo Energy Earns Great Place To Work Certification™ for Eighth Consecutive Year 
Albireo Energy Names Mergers and Acquisitions Executive 
Albireo Energy Strengthens Presence in Arizona with Local Leadership and Proven Expertise 
Albireo Energy Launches Private Cloud Services to Enhance Building System Data Security and Performance 
Albireo Launches Critical Alarm Management Service for Mission Critical Buildings that Require Uptime and Reliability 
Albireo Energy Sees Buildings in a Different Way as it Unveils New Brand Identity 
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year? 
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations 
Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)
Your note
Sign in to keep a note on ALBO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER MARTHA J | Officer | Sale | Jan 22, 2023 | 14,506 |
| COOPER RONALD HAROLD WILFRED | Chief Executive Officer | Sale | Jan 22, 2023 | 57,444 |
| DUNCAN JASON G | General Counsel | Sale | Jan 22, 2023 | 14,146 |
| GRAHAM MICHELLE | Officer | Sale | Jan 22, 2023 | 24,493 |
| HARFORD SIMON N R | Chief Financial Officer | Sale | Jan 22, 2023 | 32,689 |
| HOPKINSON CRAIG C M.D. | Director | Stock Award(Grant) | Nov 30, 2022 | 10,495 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 9.45% | 1,956,488 | 86.38M | Dec 30, 2022 |
| Perceptive Advisors Llc | 8.49% | 1,757,160 | 77.58M | Dec 30, 2022 |
| Deep Track Capital, LP | 8.23% | 1,704,000 | 75.23M | Dec 30, 2022 |
| Chicago Capital, LLC | 6.58% | 1,362,484 | 60.15M | Dec 30, 2022 |
| Blackrock Inc. | 6.50% | 1,344,897 | 59.38M | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 4.58% | 948,532 | 41.88M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 5.35% | 1,108,422 | 48.94M | Oct 30, 2022 |
| Federated Hermes Kaufmann Small Cap Fund | 3.94% | 815,354 | 36.00M | Oct 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.87% | 593,770 | 26.21M | Sep 29, 2022 |
| iShares Russell 2000 ETF | 1.97% | 407,557 | 17.99M | Dec 30, 2022 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.46% | 301,243 | 13.30M | Oct 30, 2022 |
| Meridian Small Cap Growth Fund | 1.20% | 248,293 | 10.96M | Sep 29, 2022 |